How to Afford CPAP + GLP-1 Polytherapy
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
Only 1% of Australians with insomnia access CBT-I, according to Flinders University researchers who are calling for changes to improve access to this proven non-drug treatment.
Indicated for moderate-to-severe OSA patients with obesity, adults taking the medication had at least 25 fewer breathing interruptions each hour as they slept. After one year, up to 50% no longer had symptoms associated with OSA.
The AASM issued a statement in response to the FDA’s approval of Zepbound for OSA patients with obesity, highlighting its potential as a new treatment option while cautioning about its limitations and the importance of sustained weight loss.
Read MoreThe treatment is designed to improve snoring by tightening the soft palate and reducing vibrations that cause patients to snore.
Read MoreAn American Heart Association initiative selected the oral negative pressure therapy for its potential to improve heart and brain outcomes in people with OSA.
Read MoreThe launch is marked by the first successful patient implants at University College London Hospitals.
Read MoreResults from a social media analysis and survey of people with narcolepsy uncover challenges with twice-nightly oxybate therapy.
Read MoreRemote CPAP setup solutions are changing how patients access care—but are they as effective as in-person setups?
Read MoreThe collaboration combines Happy Sleep’s FDA-cleared home sleep testing and monitoring tools with Dentulu’s network of licensed dentists who provide custom oral appliances.
Read MorePatients receiving peer mentorship used their CPAP machines more consistently, averaging 4.5 hours per night compared to 3.7 hours for those receiving standard care.
Read MoreThe awards will support 13 clinical effectiveness research studies, including three focused on sleep interventions.
Read MoreThe CareCredit health and wellness credit card is now accepted as a payment option for Daybreak’s sleep testing kits and oral appliance.
Read MoreThe Illuminate Hypersomnia Adjunct Scientific Meeting on Feb 13, 2025, will address challenges in idiopathic hypersomnia drug development.
Read MoreAXS-12, a norepinephrine reuptake inhibitor, significantly reduced cataplexy attacks in narcolepsy patients in the ENCORE phase 3 trial, demonstrating long-term efficacy, safety, and improvements in excessive daytime sleepiness and cognition.
Read MoreSmile N’ Style Dental in Carmel, Ind, is now offering oral appliance therapy as an alternative treatment for obstructive sleep apnea.
Read MoreThe suit alleges that a nurse practitioner sexually assaulted a patient during a routine examination and that the clinic failed to act on the patient’s request to be scheduled elsewhere.
Read MoreA report from ProPublica says that Lincare was supposed to supply the most ailing patients with new CPAPs but instead diverted the devices to new customers who would deliver greater profits for the company.
Read More